For example, dual incretin therapies have been gaining increasing attention for promoting weight loss, with dual receptor agonists (e.g., tirzepatide), targeting both GIP (glucose‐inhibitory polypeptide) and GLP‐1 receptors, outperforming GLP‐1 receptor agonists alone in terms of weight loss and improving glycemic control in patients with type 2 diabetes.137. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.